Table 3. Subsequent neoplasms . All... | American Society of Hematology

Table 3.

Subsequent neoplasms

	All patients (N = 703)	≥18 years (n = 209)	<18 years (n = 494)	<3 years (n = 54)
Subsequent neoplasm	8 (1.1)	3 (1.4)	5 (1.0)	1 (1.9)
ALL to AML lineage switch	5 (62.5)	3 (100)	2 (40)	1 (100)
Myelodysplasia (MDS)	2 (25)	0	2 (40)	0
Other new malignancy∗	1 (12.5)	0	1 (20)	0
Time from infusion to subsequent neoplasm,† median (range), d	83 (24-728)	73 (35-93)	155 (24-728)	42 (42-42)

	All patients (N = 703)	≥18 years (n = 209)	<18 years (n = 494)	<3 years (n = 54)
Subsequent neoplasm	8 (1.1)	3 (1.4)	5 (1.0)	1 (1.9)
ALL to AML lineage switch	5 (62.5)	3 (100)	2 (40)	1 (100)
Myelodysplasia (MDS)	2 (25)	0	2 (40)	0
Other new malignancy∗	1 (12.5)	0	1 (20)	0
Time from infusion to subsequent neoplasm,† median (range), d	83 (24-728)	73 (35-93)	155 (24-728)	42 (42-42)

Safety-evaluable set. Data are presented as n (%).

MDS, myelodysplastic syndrome.

The type of new malignancy was not reported.

Inclusive of lineage switch.